BDSX News and Press, Biodesix Inc. From 10/03/23

Studies highlight the clinical utility and real-world impact of the Nodify CDT® and Nodify XL2® tests in managing both benign and malignant pulmonary nodules. Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced th...

New data highlights two novel proteomic tests that support treatment decision making in patients with non-small cell lung cancer (NSCLC): Expanded analysis of the VeriStrat ® host immune classifier’s ability to predict immune checkpoint inhibition (ICI) response in patie...

Data demonstrates a 51% relative increase in the proportion of lung nodule biopsies diagnosing cancer Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that a new analysis from the post-market, prospective, re...

2023-08-07 18:43:07 ET Biodesix, Inc. (BDSX) Q2 2023 Earnings Conference Call August 07, 2023 04:30 PM ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper Cowie - Chief Financial Officer Conference ...

2023-08-07 16:52:43 ET Biodesix press release ( NASDAQ: BDSX ): Q2 GAAP EPS of -$0.17 beats by $0.04 . Revenue of $11.9M (+8.7% Y/Y) beats by $0.25M . For further details see: Biodesix GAAP EPS of -$0.17 beats by $0.04, revenue of $11.9M beats by $0.25M

Second quarter 2023 Core Lung Diagnostic revenue of $11.4 million increased 58% over the comparable period in 2022 and 33% over the first quarter of 2023; Second quarter 2023 gross profit margin of 73% versus 64% for the second quarter 2022 and 65% for the first quarter 2023; Reve...

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton, Chief Executive Officer of Biodesix, will present and host in-person 1x1 investor meetings at the Canaccord Genuity 43rd Annual Growth Conference, w...

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, announced today that it will release financial results for the second quarter ended June 30, 2023 after the close of trading on Monday, August 7. Biodesix’s management will hos...

2023-07-12 09:45:46 ET A medical diagnostics & screening company based out of Boulder, Colorado is causing quite the stir already on Wednesday morning after the company announced “that the prospective, real-world ORACLE study (An Observational Registry Study to Evaluate the Perfo...

2023-07-12 09:27:52 ET Biodesix ( NASDAQ: BDSX ) jumped ~10% in the pre-market trading Wednesday after announcing that the science journal PLOS ONE published data from its ORACLE study, which returned positive results for the company’s Nodify XL2 Test designed for early d...